Study S002590

A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT06854952
Acronym: FALCON
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 167
Start: 2025-03-07
Primary completion: 2025-08-19
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions: Overweight or Obesity
Interventions: DRUG:TERN-601; OTHER:Matching Placebo
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Percent Change in Body Weight [12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004304	Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. Garvey WT, Obesity (Silver Spring, Md.)	2026	Randomized trial	PMID 42528333 DOI	cites ClinicalTrials.gov:NCT06854952; registry reference DERIVED:42528333